These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 18388038

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication.
    Castaño G, Más R, Roca J, Fernández L, Illnait J, Fernández JC, Selman E.
    Angiology; 1999 Feb; 50(2):123-30. PubMed ID: 10063942
    [Abstract] [Full Text] [Related]

  • 4. A long-term study of policosanol in the treatment of intermittent claudication.
    Castaño G, Más Ferreiro R, Fernández L, Gámez R, Illnait J, Fernández C.
    Angiology; 2001 Feb; 52(2):115-25. PubMed ID: 11228084
    [Abstract] [Full Text] [Related]

  • 5. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study.
    Castaño G, Más R, Fernández L, Gámez R, Illnait J.
    Angiology; 2003 Jan; 54(1):25-38. PubMed ID: 12593493
    [Abstract] [Full Text] [Related]

  • 6. Concomitant use of policosanol and beta-blockers in older patients.
    Castaño G, Mas R, Gámez R, Fernández J, Illnait J, Fernández L, Mendoza S, Mesa M, Gutiérrez JA, López E.
    Int J Clin Pharmacol Res; 2004 Jan; 24(2-3):65-77. PubMed ID: 15689053
    [Abstract] [Full Text] [Related]

  • 7. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients.
    Arruzazabala ML, Más R, Molina V, Carbajal D, Mendoza S, Fernández L, Valdés S.
    Int J Tissue React; 1998 Jan; 20(4):119-24. PubMed ID: 10093795
    [Abstract] [Full Text] [Related]

  • 8. A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia.
    Alcocer L, Fernández L, Campos E, Más R.
    Int J Tissue React; 1999 Jan; 21(3):85-92. PubMed ID: 10645516
    [Abstract] [Full Text] [Related]

  • 9. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication.
    Gresele P, Migliacci R, Procacci A, De Monte P, Bonizzoni E.
    Thromb Haemost; 2007 Mar; 97(3):444-50. PubMed ID: 17334512
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA, Pande RL, Hiatt WR.
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [Abstract] [Full Text] [Related]

  • 11. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.
    Cleanthis M, Bhattacharya V, Smout J, Ashour H, Stansby G.
    Eur J Vasc Endovasc Surg; 2009 May; 37(5):604-10. PubMed ID: 19297212
    [Abstract] [Full Text] [Related]

  • 12. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients.
    Stüsser R, Batista J, Padrón R, Sosa F, Pereztol O.
    Int J Clin Pharmacol Ther; 1998 Sep; 36(9):469-73. PubMed ID: 9760006
    [Abstract] [Full Text] [Related]

  • 13. A preliminary study on the effects of exercising to maximum walking distance on platelet and endothelial function in patients with intermittent claudication.
    Collins P, Ford I, Ball D, Macaulay E, Greaves M, Brittenden J.
    Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):266-73. PubMed ID: 16360327
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of arm-ergometry versus treadmill exercise training to improve walking distance in patients with claudication.
    Treat-Jacobson D, Bronas UG, Leon AS.
    Vasc Med; 2009 Aug; 14(3):203-13. PubMed ID: 19651669
    [Abstract] [Full Text] [Related]

  • 15. Treadmill exercise in claudicants on aspirin results in improved antioxidant status but only minimal platelet activation.
    Cleanthis M, Smout J, Bhattacharya V, Ashour H, Shenton B, Stansby G.
    Platelets; 2005 Dec; 16(8):446-52. PubMed ID: 16287611
    [Abstract] [Full Text] [Related]

  • 16. Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
    Prescrire Int; 2009 Apr; 18(100):56-9. PubMed ID: 19585717
    [Abstract] [Full Text] [Related]

  • 17. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
    Gresele P, Migliacci R, Arosio E, Bonizzoni E, Minuz P, Violi F, NCX 4016-X-208 Study Group.
    J Vasc Surg; 2012 Dec; 56(6):1622-8, 1628.e1-5. PubMed ID: 22963812
    [Abstract] [Full Text] [Related]

  • 18. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR, Dale RA, Creager MA, Lipicky RJ, Constant J, Campbell LA, Hiatt WR.
    Circulation; 2009 Jan 27; 119(3):452-8. PubMed ID: 19139383
    [Abstract] [Full Text] [Related]

  • 19. Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication.
    Mortensen UM, Nielsen-Kudsk JE, Sondergaard HM, Jakobsen P, Jensen BS, Schmitz O, Nielsen TT.
    Diabet Med; 2006 Mar 27; 23(3):327-30. PubMed ID: 16492219
    [Abstract] [Full Text] [Related]

  • 20. Effects of policosanol on patients with ischemic stroke: a pilot open study.
    Ortega LL, Sánchez J, Más R, Fernández L, Mendoza S, Gámez R, Fernández JC, Illnait J, Alvarez E.
    J Med Food; 2006 Mar 27; 9(3):378-85. PubMed ID: 17004902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.